HIV/HCV Coinfection: Not a Special Population Anymore?
Abstract
The global burden of HCV/HIV co-infection is estimated at 2.3 million people worldwide. Until recently, HCV treatment in this population has been limited by poor efficacy and lower rates of sustained virologic response (SVR) as compared to those achieved in mono-infected populations. However, the introduction of direct acting antiviral medications (DAAs) has revolutionized therapy for co-infected patients, and resulted in dramatic improvements in response to treatment, with SVR rates exceeding 95% in HIV infected patients. In addition to increased effectiveness, the DAAs have excellent safety profiles and can be co-administered concurrent with antiretroviral medications. Several of these pangenotypic HCV regimens are reviewed in this paper, along with relevant antiretroviral drug interactions to be aware of during therapy.
Keywords
Full Text:
Subscribers OnlyReferences
Platt L, Easterbrook P, Gower E, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(7): 797-808
The Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modeling study. Lancet Gastroenterol Hepatol. 2017; 2(3): 161-76.
Pineda JA, , Romero-Gumez M, Diaz-Garcia F, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology. 2005; 41(4): 779-89.
Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013; 158(9): 658-66.
Kozeil MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med. 2007; 356(14): 1445-54.
Merchante N, Girón-González JA, González-Serrano M, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS. 2006; 20(1):49-57.
Tsui JI, Cheng DM, Libman H, et al. Hepatitis C virus infection is associated with painful symptoms in HIV-infected adults. AIDS Care. 2012; 24(7): 820-7.
Goodgame B, Shaheen NJ, Galanko J, et al. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003; 98(11): 2535-42.
Libman H, Saitz R, Nunes D, et al. Hepatitis C infection is associated with depressive symptoms in HIV-infected adults with alcohol problems. Am J Gastroenterol. 2006; 101(8):1804-10.
Sullivan PS, Hanson DL, Teshale EH, et al. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. AIDS. 2006; 20(8): 1171-9.
Chun HM, Carpenter RJ, Macalino GE, et al. The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature. J Sex Transm Dis. 2013; doi: 10.1155/2013/176459. Epub 2013 Jun 24.
Chen TY, Ding EL, Seage Iii GR, et al. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis. 2009; 49(10):1605-15.
Feuth T, Arends JE, Fransen JH, et al. Complementary role of HCV and HIV in T-cell activation and exhaustion in HIV/HCV coinfection. PLoS One. 2013; 8(3):e59302.
Rallón N, Garcia M, Garcia-Samaniego J, et al. HCV coinfection contributes to HIV pathogenesis by increasing immune exhaustion in CD8 T-cells. PLoS One. 2017; 12(3):e0173943.
Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepatitis. 2006; 13: 34-41.
Grebely J, Page K, Sacks-Davis R, et al. The effects of female sex, viral genotype and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. J Hepatol. 2014; 59: 109-20.
Piasecki BA, Lewis JD, Reddy, et al. Influence of alcohol use, race, and viral coinfections on spontaneous HCV clearance in a US veteran population. Hepatology. 2004; 40(4):892-9.
Simmons B, Saleem J, Hill A, et al. Risk of late relapse or reinfection with hepatitis C virus after achieving a sustained virological response: a systematic review and meta-analysis. Clin Infect Dis. 2016; 62(6): 683-94.
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol. 2014; 61: S58-68.
Foster GR, Irving WL, Cheung MCM, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016; 64: 1224-31.
Berenguer J, Zamora FX, Carrero A, et al. Effects of sustained viral response in patients with HIV and chronic hepatitis C and nonadvanced liver fibrosis. J Acquir Immune Defic Syndr. 2014; 66(3): 280-7.
Bhattacharya D, Belperio PS, Shahoumian TA, et al. Effectiveness of all-oral antiviral regimens in 996 human immunodeficiency virus/hepatitis C virus genotype 1-coinfected patients treated in routine practice. Clin Infect Dis. 2017; 64(12): 1711-20.
Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351(5):438-50.
Kohli A, Kattakutzhy S, Sidharthan S, et al. Four-week direct-acting antiviral regimens in noncirrhotic patients with hepatitis C virus genotype 1 infection: an open-label, nonrandomized trial. Ann Intern Med. 2015; 163(12): 899-907.
Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014; 312(4): 353-61.
Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015; 385(9973): 1098-106.
Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015; 313(12): 1232-9.
Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015; 373(8): 705-13.
Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015; 313(12): 1223-31.
Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med 2015; 313(8): 714-25.
Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015; 2(8): e319-27.
Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med 2017; 166(9): 637-48.
Sofosbuvir drug facts. Gilead.com. Published April 2017. Accessed Sept 2017.
Wyles DL, Bräu N, Kottilil S, et al. Sofosbuvir and velpatasvir for the treatment of HCV in patients coinfected with HIV-1: an open-label, phase 3 study. Clin Infect Dis. 2017; Mar 29. doi: 10.1093/cid/cix260.
Zeuzem S, Feld J, Wang S, et al. ENDURANCE-1: a phase 3 evaluation of the efficacy and safety of 8- versus 12-week treatment with glecaprevir/pibrentasvir (formerly ABT-493/ABT-530) in HCV genotype 1 infected patients with or without HIV-1 co-infection and without cirrhosis. The AASLD Liver Meeting. Boston, November 11-15, 2016. Abstract 253.
Rockstroh J, Lacombe K, Viani R, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients co-infected with hepatitis C and human immunodeficiency virus-1: the EXPEDITION-2 study. 9th International AIDS Society Conference on HIV Science. Paris, July 23-26, 2017. Abstract MOAB0303.
Pradat P, Pugliese P, Poizot-Martin I, et al. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-infected patients - "en route for eradication”? J Infect. 2017; 75(3): 234-41.
Meissner EG, Suffredini AF, Kottilil S. Opportunities in proteomics to understand hepatitis C and HIV coinfection. Future Virol. 2012; 7(8): 759-65.
Al-Salama ZT, Deeks ED. Elbasvir/Grazoprevir: A Review in Chronic HCV Genotypes 1 and 4. Drugs. 2017; 77(8): 911-21.
Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 Phase 3 randomized trials. Gastroenterology. 2017; 153(1): 113-22.
Soriano V, Benítez-Gutiérrez L, Arias A, et al. Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. Expert Opin Drug Metab Toxicol. 2017; 13(9): 1015-22.
DOI: http://dx.doi.org/10.18103/imr.v3i12.588
Refbacks
- There are currently no refbacks.